» Articles » PMID: 20080469

Supportive Care for Patients with Early Breast Cancer

Overview
Specialty Oncology
Date 2010 Jan 19
PMID 20080469
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer treatment currently requires the joint efforts of a multidisciplinary team to effectively combine chemotherapy, hormone therapy, biological agents, surgery and radiation therapy when needed. To develop such a treatment plan, it is important to know the benefits as well as the potential toxic effects of each therapy. Thus, many patients with early breast cancer complain of collateral adverse events such as fatigue, nausea, vomiting, loss of libido, hot flashes, night sweats or neuropathy due to the complex therapies they are receiving. To date, the treatment of such symptoms is an important issue that greatly affects the quality of life of these patients. In this review, we report the content of a multi-expert meeting where the incidence of and medical approach to some of the most common adverse events encountered during the treatment of patients with early breast cancer were analysed.

Citing Articles

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer.

Wohlrab J, Bangemann N, Kleine-Tebbe A, Thill M, Kummel S, Grischke E Breast Cancer (Dove Med Press). 2014; 6:115-22.

PMID: 25114589 PMC: 4126578. DOI: 10.2147/BCTT.S61699.


Breast cancer medications and vision: effects of treatments for early-stage disease.

Eisner A, Luoh S Curr Eye Res. 2011; 36(10):867-85.

PMID: 21819259 PMC: 3205820. DOI: 10.3109/02713683.2011.594202.

References
1.
Dalal S, Zhukovsky D . Pathophysiology and management of hot flashes. J Support Oncol. 2006; 4(7):315-20, 325. View

2.
Howell A, Robertson J, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg U . Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002; 20(16):3396-403. DOI: 10.1200/JCO.2002.10.057. View

3.
McNeely M, Campbell K, Rowe B, Klassen T, Mackey J, Courneya K . Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006; 175(1):34-41. PMC: 1482759. DOI: 10.1503/cmaj.051073. View

4.
Lyman G . Risks and consequences of chemotherapy-induced neutropenia. Clin Cornerstone. 2007; 8 Suppl 5:S12-8. DOI: 10.1016/s1098-3597(06)80054-2. View

5.
Broeckel J, Jacobsen P, Horton J, Balducci L, Lyman G . Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol. 1998; 16(5):1689-96. DOI: 10.1200/JCO.1998.16.5.1689. View